DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Fasudil is an investigational drug.
There have been 9 clinical trials for Fasudil. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2010.
The most common disease conditions in clinical trials are Motor Neuron Disease, Amyotrophic Lateral Sclerosis, and Myocardial Infarction. The leading clinical trial sponsors are Brigham and Women's Hospital, Johns Hopkins University, and RenJi Hospital.
There are eight hundred and twenty-one US patents protecting this investigational drug and eight international patents.
Recent Clinical Trials for Fasudil
|Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction||RenJi Hospital||Phase 4|
|Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS||University Medical Center Goettingen||Phase 2|
|Red Blood Cell ATP Release and Vascular Function in Humans||Colorado State University||Phase 2|
Top disease conditions for Fasudil
Top clinical trial sponsors for Fasudil
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Fasudil||Start Trial||Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|Fasudil||Start Trial||Use of anthelmintic agents against Dirofilaria immitis||Intervet Inc. (Madison, NJ)||Start Trial|
|Fasudil||Start Trial||Diarylimidazole compound and harmful organism control agent||Nippon Soda Co., Ltd. (Tokyo, JP)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Fasudil||European Patent Office||2981556||2033-04-02||Start Trial|
|Fasudil||World Intellectual Property Organization (WIPO)||2014165513||2033-04-02||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|